Atty Dkt 8325-1004 M4-US1 PATENT

RECEIVED TECHCENTER TOURS I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on 30-JANUARY -2002

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

WANG and PABO

Serial No.: 09/636,243

Filing Date: August 10, 2000

Group Art Unit: 1645

Examiner: Bhatti, Tahira H.

Title: DIMERIZING PEPTIDES

## TRANSMITTAL LETTER

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed November 30, 2001 enclosed are the following:

- a copy of the Notice to Comply with Requirements for Patent Applications 1) Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
  - 2) a Petition for Extension of Time;
- 3) a Preliminary Amendment w/ attached Version with markings to show changes made;
  - 4) a Declaration Under 37 CFR §1.825;
  - 5) a Sequence Listing in paper form and computer readable form; and
  - a check in the amount of \$110 to cover the extension of time fee. 6)

Atty Dkt 8325-1004 M4-US1 USSN: 09/636,243

**PATENT** 

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 18-1648.

Respectfully submitted,

Date: <u>Jan 30, 2002</u>

Dahna S. Pasternak Registration No. 41,411

ROBINS & PASTERNAK LLP 90 Middlefield Road, Suite 200 Menlo Park, CA 94025 Telephone: (650) 325-7812

Facsimile: (650) 325-7823



## United States Patent and Trademark Office

	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/636,243	08/10/2000	Bryan S. Wang	8325-0004	6438
	7590 11/30/2001	RECEIVED		·
ROBINS & ASSOCIATES Suite 200 90 Middlefield Road  Menlo Park, CA 94025		REGERTED	EXAMINER	
		DEC = 7 2001 BHATTI, TAR		HIRA H
Menlo Park, CA 94025		DADUG C DICTEDUAL LI C	ART UNIT	PAPER NUMBER
المين		ROBINS & PASTERNAK LLP	1627	
2002			DATE MAILED: 11/30/2001	
MACH se find below	and/or attached an	ROBINS & PASTERNAK LLP  Description of the control	ning this application or	proceeding.

DOCKETEDDSP 8325-1004 Seq Lint 12/30/01 LD 5/30/02



UNITEL ATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER FILING DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NO.

EXAMINER

Tahira Bhatti

ART UNIT PAPER NUMBER

1627
DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication should be directed to Tahira Bhatti whose telephone number is (703) 605-1203. The examiner can normally be reached on Monday through Friday from 8:00 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jyothsna Venkat, can be reached at (703)308-2439. The fax number for this group is (703)305-3014.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the group receptionist whose telephone number is (703)308-0196.

Tahira Bhatti
Patent Examiner
Technology center 1600
Art Unit 1627
Nov 27, 2001

BENNETT CELSA PRIMABY EXAMINER

1111100 111111

## Application No.: 09 1/35,243 NOTICE TO COMPL. VITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	X	<ol> <li>This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.</li> </ol>
OIPESO	X	<ol> <li>This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).</li> </ol>
B 0 5 20C2	Ø	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
R-1DEMAS*		4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
		5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
		6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
		7. Other:
	App	olicant Must Provide:
	X	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).  7. Other:  An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".  An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
	X	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
	X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
	For	questions regarding compliance to these requirements, please contact:
	For For	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 entIn Software Program Support (SIRA)
		Technical Assistance

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE